“In the prior clinical studies of more than 11,000 patients, tanezumab demonstrated clinically meaningful efficacy vs. placebo and other select commonly used pain medicines. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. Studies in terminal cancer pain were allowed to proceed.
“We are pleased with the FDA’s decision as chronic pain remains an area of significant unmet medical need and we believe tanezumab has potential to offer a new, non-narcotic option,” said Steve Romano, MD, senior vice president and head of Global Medicines Development at Pfizer’s Global Innovative Pharmaceuticals Business.
“We’re pleased to work with Pfizer to resume the Phase 3 program, and we’re confident that tanezumab, if approved, can be an innovative treatment with the potential to help millions suffering from painful conditions,” said David Ricks, Lilly senior vice president and president, Lilly Bio-Medicines.
It is estimated that nearly one in five adults suffer from chronic pain”
This is actually really exciting. I had an interview with a pain biologist, and he was talking about the major advances in the field that are being translated into drugs. Basically, pain involves the activation of opioid receptors, which is why opium and heroin and stuff (which block this activation) have historically been used as pain medications. Unfortunately, they are also super addictive. The big thing now is to develop an antibody-based system, where an antibody binds to the proteins that activate pain receptors. This shouldn’t be addictive.
No comments:
Post a Comment